Search

Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial

Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.

Read more

European Hematologists will discuss breakthroughs in blood disorders in Milan, Italy - June 12-15, 2014

About the EHA Annual Congress

Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases of blood and their treatments.

Read more

EHA Friends' Fund

Together, we can change the lives of many and make greater strides in the treatment of patients with blood disorders.

Read more

A European Reference Network for Rare Hematological Diseases

You may have heard of European Reference Networks (ERNs). But most likely you have not. ERNs are networks of specialized hospital departments and research centers to treat rare or low-prevalent complex diseases.

Read more

EHA ‘Excellence in Hematology’ Survey now online

Excellence in Hematology is created together. Would you help us out?

This week, we’re starting an important research endeavor – our ‘Excellence in hematology’ survey.

Read more

Targeting the B-cell Receptor in Aggressive B-cell Lymphomas

In collaboration with Dr. Lou Staudt, Pharmacyclics and associate investigators, we performed a clinical trial of a very potent inhibitor of Bruton Tyrosine Kinase (BTK) called ibrutinib.

Read more

Streamlining SoHO Management in EU Hospitals

The European Commission's Directorate-General for Health and Food Safety (DG SANTE) is committed to improving the management of Substances of Human Origin (SoHO) in EU hospitals.

Read more